Arch Biopartners Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ACHFF research report →
About the company
Arch Biopartners Inc. is a biotechnology company focused on developing innovative technologies with significant medical and commercial potential. Their primary endeavor involves advancing Metablok, a lead drug candidate designed to treat or prevent dipeptidase-1 (DPEP-1) mediated inflammation in critical organs like the lungs, liver, and kidneys.
- CEO
- Richard Gabriel Muruve
- IPO
- 2002
- Employees
- 6
- HQ
- Toronto, ON, CA
Price Chart
- Market Cap
- $41.30M
- P/E
- -23.47
- P/S
- 0.00
- P/B
- -16.90
- EV/EBITDA
- -27.80
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 70.15%
- ROIC
- 266.32%
- Revenue
- $0 · -100.00%
- Net Income
- $-1,552,744 · 60.39%
- EPS
- $-0.02 · 61.65%
- Op Income
- $-1,499,812
- FCF YoY
- 31.95%
- 52W High
- $1.31
- 52W Low
- $0.29
- 50D MA
- $0.38
- 200D MA
- $0.64
- Beta
- 1.89
- Avg Volume
- 29.08K
Get TickerSpark's AI analysis on ACHFF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our ACHFF coverage
Recent articles, reports, and earnings notes.
No research on ACHFF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ACHFF report →Similar companies
Peers in the same neighborhood.